6/28/23, 10:00 PM ERSPC Pathway Feedback Search Clinical Topics Home Studies ERSPC ERSPC Disease Prostate cancer Trial question What is the role of PSA testing in men for prostate cancer screening? Study design Multi-center Open label RCT Population 162243 male patients Inclusion criteria: men between the ages of 55 and 69 years Key exclusion criteria: diagnosis of prostate cancer Interventions N=72890 prostate cancer screening (PSA screening at an average of once every 4 years) N=89353 no screening (did not receive PSA screening) Primary outcome Death from prostate cancer 0.4 % 0.36 0.29 0.3 % 0.2 % Significant decrease 0.1 % NNT = 1429 0.0 % Prostate cancer screening No screening Significant decrease in death from prostate cancer (0.29% vs. 0.36%; aRR 0.8, 95% CI 0.65 to 0.98) Conclusion https://web.pathway.md/studies/recnOU5pM0aagYlhx 1/2 6/28/23, 10:00 PM ERSPC Pathway In men between the ages of 55 and 69 years, prostate cancer screening was superior to no screening with respect to death from prostate cancer. Reference Schroder FH, Hugosson J, Roobol MJ et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009 Mar 26;360(13):1320-8. Open reference URL https://web.pathway.md/studies/recnOU5pM0aagYlhx 2/2